Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other solid neoplasm 1Gynecologic 1Genitourinary 1Dermatologic 1

Conditions

Breast Neoplasms 20Pancreatic Neoplasms 19Carcinoma, Non-Small-Cell Lung 17Ovarian Neoplasms 16Fallopian Tube Neoplasms 12Triple Negative Breast Neoplasms 10Neoplasm Metastasis 10Carcinoma, Ovarian Epithelial 10Unspecified Adult Solid Tumor, Protocol Specific 8Neoplasms 7Lung Neoplasms 7Endometrial Neoplasms 7Esophageal Neoplasms 6Brenner Tumor 6Breast Neoplasms, Male 6Stomach Neoplasms 5Melanoma 5Squamous Cell Carcinoma of Head and Neck 4Peritoneal Neoplasms 3Gallbladder Neoplasms 3Cholangiocarcinoma 3Adenocarcinoma of Lung 3Adenocarcinoma 3Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Salivary Gland Neoplasms 2Prostatic Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma, Non-Hodgkin 2Leukemia, Lymphocytic, Chronic, B-Cell 2

Interventions

Taxes 1Immunoglobulin G 1Disulfides 1Bevacizumab 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Cervical Adenocarcinoma × Taxes × Clear all
NCT02020707 2024-07-26

Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers

Mayo Clinic

Phase 1 Completed
43 enrolled
DermatologicGenitourinaryGynecologicOther solid neoplasmSarcoma

Cervical Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡